Litcius/Paper detail

Fulminant myocarditis as an early presentation of SARS-CoV-2

Tamara Naneishvili, Arsalan Khalil, Ryan O’Leary, Neeraj Prasad

2020BMJ Case Reports33 citationsDOIOpen Access PDF

Abstract

Myocarditis is well known to be caused by viral infections such as Coxsackie virus group B, human herpes virus 6 and parvovirus B19. However, during the current emerging outbreak of SARS-CoV-2, there have been few case reports describing myocarditis as a possible presentation. In our case report we describe, early cardiac manifestations of SARS-CoV-2 in a UK District General Hospital. A 44-year-old Caucasian woman without any comorbidities presented with SARS-CoV-2 related fulminant myocarditis without initial respiratory symptoms. Patient underwent treatment with milrinone and methylprednisolone that showed reduction in myocardial inflammation and significantly improved myocardial contractility. This was then followed by a second phase of SARS-CoV-2 associated pneumonia and renal failure requiring ventilatory support and haemofiltration. Although, not described in the literature, we have found conjunctive use of milrinone and methylprednisolone effective in patient with SARS-CoV-2 fulminant myocarditis.

Topics & Concepts

MyocarditisFulminantMilrinoneMedicineMethylprednisolonePneumoniaInternal medicineCardiologyHeart failureViral Infections and Immunology ResearchSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies